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The emerging interest in circulating tumor DNA (ctDNA) analyses for clinical
trials has necessitated the development of a high-throughput method for fast,
reproducible, and efficient isolation of ctDNA. Currently, the majority of
ctDNA studies use the manual QIAamp (QA) platform to isolate DNA from
blood. The purpose of this study was to compare two competing automated
DNA isolation platforms [Maxwell (MX) and QIAsymphony (QS)] to the cur-
rent ‘gold standard’ QA to facilitate high-throughput processing of samples in
prospective trials. We obtained blood samples from healthy blood donors and
metastatic cancer patients for plasma isolation. Total cell-free DNA (cfDNA)
quantity was assessed by TERT quantitative PCR. Recovery efficiency was
investigated by quantitative PCR analysis of spiked-in synthetic plant DNA.
In addition, a b-actin fragmentation assay was performed to determine the
amount of contamination by genomic DNA from lysed leukocytes. ctDNA
quality was assessed by digital PCR for somatic variant detection. cfDNA
quantity and recovery efficiency were lowest using the MX platform, whereas
QA and QS showed a comparable performance. All platforms preferentially
isolated small (136 bp) DNA fragments over large (420 and 2000 bp) DNA
fragments. Detection of the number variant and wild-type molecules was most
comparable between QA and QS. However, there was no significant difference
in variant allele frequency comparing QS and MX to QA. In summary, we
show that the QS platform has comparable performance to QA, the ‘gold
standard’, and outperformed the MX platform depending on the readout
used. We conclude that the QS can replace the more laborious QA platform,
especially when high-throughput cfDNA isolation is needed.
1. Introduction
With the discovery of cell-free DNA (cfDNA), first
described in 1948 by Mandel and Metais (1948), and
subsequently circulating tumor DNA (ctDNA; Stroun
et al., 1989), a novel biomarker in cancer research
became available. Since then, many studies have
shown its great potential for detecting minimal resid-
ual disease and evaluating treatment response (Bidard
et al., 2014; Dawson et al., 2013; Diaz and Bardelli,
2014; Diehl et al., 2008; Forshew et al., 2012;
Herbreteau et al., 2018; Murtaza et al., 2013; Pugh,
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2018; Shinozaki et al., 2007). However, to enable high-
throughput ctDNA analyses a fast, accurate, and effi-
cient cfDNA isolation method is highly needed.
Currently, the majority of ctDNA studies use Qia-
gen’s QIAamp (QA) platform for cfDNA isolation
(Oxnard et al., 2014; Sefrioui et al., 2015; Zill et al.,
2015). However, this manual platform is laborious and
can only process up to 24 samples at a time rendering
this method less suitable for large-scale studies.
Automation of cfDNA isolation represents a potential
solution provided that it is able to (a) reduce hands-on
time; (b) simultaneously process large numbers of sam-
ples; (c) accurately and reproducibly isolate cfDNA
with a reasonable recovery; and (d) preserve the qual-
ity of ctDNA for downstream analyses.
Cell-free DNA is naturally fragmented (140–175 bp)
and only present at low concentrations in the blood cir-
culation (usually around 10 ng per mL plasma; Fleis-
chhacker and Schmidt, 2007). In addition, the fraction
of ctDNA relative to cfDNA can vary from extremely
low (< 0.01%) to very high (60%), as it is dependent on
tumor type and stage (Bettegowda et al., 2014; Diehl
et al., 2008). Together these features make it imperative
to carefully determine the efficacy of DNA isolation
instead of merely investigating isolation yields. Further-
more, isolation of cfDNA and ctDNA therein is highly
susceptible to genomic DNA contamination from lysed
leukocytes (Elshimali et al., 2013; Jahr et al., 2001),
resulting in a potential underestimation of the ctDNA
fraction and decreasing the detection sensitivity. As po-
tential differences in cfDNA recovery efficiency between
isolation methods might affect downstream analysis
results of ctDNA by decreasing its detection sensitivity,
standardized comparison of the different methods for
cfDNA isolation is important and highly needed.
The purpose of this study was to compare two auto-
mated cfDNA isolation platforms, Maxwell (MX) and
QIAsymphony (QS), to the current ‘gold standard’
QA isolation kit to determine whether these automated
platforms can facilitate high-throughput processing of
samples in prospective trials. Our analyses focused on
both qualitative and quantitative parameters, including
cfDNA yield, recovery efficiency, cfDNA fragmenta-
tion patterns, and ctDNA fraction retrieved, using
optimally processed plasma samples of healthy blood
donors (HBDs) and patients with metastatic cancer.
2. Materials and methods
2.1. Subjects
Blood samples were obtained from a total of 10 HBDs
and 10 metastatic cancer patients. HBDs were either
laboratory volunteers or blood donors of the Sanquin
Blood Bank South-West Region, The Netherlands.
Patients were enrolled in this study between September
2016 and September 2017 within the Erasmus MC
Cancer Institute in Rotterdam, the Netherlands. Eligi-
bility criteria for patients have been described previ-
ously (van Dessel et al., 2017). All patients provided
written informed consent, and the institutional review
board approved the protocols (Erasmus MC ID MEC
15-616). The study methodologies conformed to the
standards set by the Declaration of Helsinki. Patient
and tumor characteristics are summarized in Table 1.
2.2. Blood collection
Healthy blood donors donated 20 mL of blood, col-
lected either in 2 9 10 mL CellSave preservative tubes
(Janssen Diagnostics, Raritan, NJ, USA) or in
1 9 10 mL EDTA tube (Becton, Dickinson and Com-
pany, Franklin Lakes, NJ, USA) and 1 9 10 mL Cell-
Save preservative tube. Patients donated 3 9 10 mL of
blood collected in CellSave preservative tubes. Blood
samples were stored at room temperature until further
processing. After blood draw, samples in EDTA tubes
were processed within 24 h, whereas samples in Cell-
Save tubes were processed within 96 h for plasma iso-
lation as previously described (van Dessel et al., 2017).
2.3. cfDNA isolation
Cell-free DNA was isolated from 2 mL of plasma and
eluted in 60 lL of the provided elution buffer. Three
isolation platforms were evaluated (Table 2):
Table 1. Patient and tumor characteristics.
Patient
ID (#)
Primary
tumor
Known somatic variant
(nucleotide change)
Variant allele
frequency in
tissue (%)
BP-001 NSCLC KRAS p.G12C (c.34G>T) 32
BP-003 Melanoma NRAS p.Q61R (c.182A>G) 88
BP-004 Melanoma BRAF p.V600E
(c.1799_1800delinsAA)
50
BP-007 Melanoma BRAF p.V600K
(c.1798_1799delGTinsAA)
38
BP-008 CRC KRAS p.G12D (c.35G>A) 45
BP-009 CRC PIK3CA p.E545K
(c.1633G>A)
45
BP-015 CRC KRAS p.G13D (c.38G>A) 40
BP-016 CRC KRAS p.G12V (c.35G>T) Unknown
BP-023 CRC KRAS p.G13D (c.38G>A) Unknown
BP-028 Melanoma BRAF p.V600K
(c.1798_1799delinsAA)
55
CRC, colorectal cancer; NSCLC, non-small-cell lung cancer.
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 QIAamp (QA) Circulating Nucleic Acid Kit
(Qiagen, Hilden, North Rhine-Westphalia, Ger-
many);
 QIAsymphony (QS) SP Circulating DNA Kit
(Qiagen);
 Maxwell (MX) RSC LV ccfDNA Plasma Cus-
tom Kit (Promega, Madison, WI, USA).
All cfDNA isolations were performed according to
the manufacturer’s protocol, with some minor modi-
fications. In more detail, cfDNA was isolated with
QA as previously described (van Dessel et al., 2017).
The QS isolation was adapted by adding 1 lg of car-
rier RNA (cRNA, Qiagen) to the plasma sample pre-
ceding isolation. Using the MX platform, a third
plasma centrifugation step at 2000 g for 10 min at
room temperature was performed after thawing to
eliminate residual leukocytes, as recommended by the
manufacturer. The custom Maxwell RSC ccfDNA
Plasma Kit for large plasma volume protocol was
used. In brief, 2 mL of plasma was added to an equal
amount of binding buffer and 140 lL of magnetic
beads. This mixture was incubated under rotation for
45 min at room temperature and subsequently cen-
trifuged at 2000 g for 1 min at room temperature.
The pelleted mix of beads and cfDNA was then
transferred to the cartridge and run on the MX
instrument (Promega) according to the manufac-
turer’s protocol.
2.4. Testing of cRNA addition to the automated
platforms
Plasma samples from several HBDs were pooled and
divided into aliquots of 2 mL each. To each aliquot,
we added different amounts of cRNA, ranging from
0.25 up to 4 lg. As a control, plasma samples without
cRNA were included. To allow determination of the
recovery efficiency, synthetic plant DNA was added to
plasma samples (see below).
2.5. cfDNA quantification
All cfDNA samples were quantified by both QubitTM
fluorometric quantitation (Invitrogen, Life Technolo-
gies, Carlsbad, CA, USA) and human TaqMan copy
number reference assay TERT (Applied Biosystems,
Life Technologies, Foster City, CA, USA) by quantita-
tive PCR (qPCR). The QubitTM measurement was per-
formed on 2 lL of each cfDNA sample using the
Quant-iT dsDNA high-sensitivity assay (Invitrogen),
according to the manufacturer’s protocol. TERT
qPCRs contained 5 lL cfDNA, 3.13 lL SensiFASTTM
SYBR Lo-Rox mix (Bioline, London, UK), and
0.62 lL TERT assay in a total reaction volume of
12.5 lL. The qPCR was performed on an Mx3000P
Real-Time PCR System (Agilent, Santa Clara, CA,
USA) with a pre-incubation at 95 °C for 10 min, fol-
lowed by 45 cycles of 95 °C for 10 s and 60 °C for
22 s. cfDNA was quantified using a standard curve of
human genomic DNA.
2.6. Synthetic plant DNA and plant DNA qPCR
assay
The synthetic plant DNA assay developed by Kang
et al. (2016) was used as an exogenous control to calcu-
late the recovery efficiency of each cfDNA isolation
method. In short, 250 ng of a 150-bp gBlocks gene
fragment (Integrated DNA Technologies Incorporation
(IDT), Coralville, IA, USA) was resuspended in LoTE
buffer to a final concentration of 1.64x100 nglL1.
Table 2. Specifications of cell-free DNA isolation platforms.
Platform Manufacturer Protocol cfDNA isolation kit
Plasma
input (mL)
Number of
samples
per run
Handling
time per
run (min) Technique
Cost (€)
per
sample
QIAamp (QA) Qiagen Manual QIAamp Circulating
Nucleic Acid Kit
1.0–5.0 24 180–240 Vacuum-column-based 20
QIAsymphony
(QS)
Qiagen Automatic QIAsymphony
Circulating
DNA Kit
2.0–8.0a 96 30 Magnetic-bead-based 24
Maxwell
(MX)
Promega Automatic Maxwell RSC
LV ccfDNA
Plasma Custom
Kit
2.0–4.0a 16b 30 Magnetic-bead-based 20
aUpon request, the manufacturer is able to adjust system settings and protocols for lower/higher plasma input volumes.
bThe Maxwell RSC 48 Instrument can process up to 48 samples per run.
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The stock sample was serially diluted to a final concen-
tration of 1.64 9 106 nglL1 of which 5 lL was
spiked into plasma preceding cfDNA isolation. Plant
DNA qPCRs were essentially performed as described
above, using 900 nM of both forward and reverse pri-
mer and 250 nM of a FAM-labeled probe (Table S1).
Recovery efficiency was determined using a standard
curve including the amount of spiked-in plant DNA.
Samples with a recovery efficiency < 5% or > 100%
were excluded from further analysis as this strongly sug-
gested an operator failure. This was further supported
by the fact that recovery efficiency was not strongly
correlated (q = 0.45) with cfDNA concentration
(Fig. S1).
2.7. Digital PCR TaqMan SNP genotyping and
b-actin fragmentation assay
The presence of somatic tumor-specific variants and
wild-type DNA molecules was determined using stan-
dard and custom-made TaqMan single nucleotide
polymorphism (SNP) genotyping assays (Thermo
Fisher Scientific, Waltham, MA, USA), according to
the manufacturer’s instructions (Tables S2 and S3). The
TaqMan b-actin assay was used to investigate the
fragment size distribution as an indication of leukocyte
DNA contamination of the cfDNA, as previously
reported (van Dessel et al., 2017). In short, a standard
amount of 2 ng of cfDNA was used to detect one small
(136 bp) and two long (420 and 2000 bp) b-actin frag-
ments within a single reaction. The used primers and
probes are indicated in Table S1. The digital PCR
(dPCR) was performed as previously described (van
Dessel et al., 2017). In short, a maximum volume input
of 7.8 lL of the final cfDNA eluate was added to the
dPCR; the dPCR run was performed on the chip-based
QuantStudio 3D Digital PCR System (Thermo Fisher
Scientific) according to the manufacturer’s protocol.
SNP genotyping assays were run at 56 °C; the b-actin
assay was run at 60 °C. A negative control (H2O) and a
positive control (cell genomic DNA with known vari-
ant) were added to every experiment.
2.8. Sample size
To test whether QS and MX were comparable to QA,
we assumed a Cohen’s effect size of 0.8, to be able to
detect relevant differences. With a two-sided type I
error probability (a) of 0.025 and a type II error prob-
ability (b) of 0.2, a power calculation determined that
18 subjects were needed for paired comparisons. Based
on the foregoing, 20 subjects were included (10 HBDs
and 10 patients).
2.9. Calculations and statistical analysis
All assay results were corrected for variations in
plasma input and eluate volume, as previously
described (van Dessel et al., 2017), and expressed as
either ngmL1 plasma or as mutant/wild-type/b-actin
copy number per mL of plasma. The variant allele fre-
quency (VAF) was calculated as follows: VAF = total
variant copy number/(total variant copy number + to-
tal wild-type copy number).
The statistical analyses and figure plotting were per-
formed in R version 3.2.3. The Friedman test was used
to test the difference between matched QA, MX, and
QS samples. Significant differences were post hoc ana-
lyzed using the Wilcoxon signed-rank test. To correct
for multiple testing, we adjusted the P value for signifi-
cance by subsequently applying the Bonferroni correc-
tion. The Wilcoxon signed-rank test was used to test
the difference between matched EDTA and CellSave
samples. Correlations were determined by Spearman’s
rank correlation coefficient.
3. Results
3.1. Optimization of cfDNA isolation using
automated isolation platforms
In a small pilot study, we had previously observed a
beneficial effect of cRNA addition to HBD plasma
during isolation with the QS protocol on the cfDNA
yield as determined by Qubit (Fig. S2). Therefore,
cRNA addition was implemented in our standard QS
protocol. However, it has been reported that cRNA
might interfere with Qubit-based DNA quantification
and might not be a reliable readout (Invitrogen, 2016).
Therefore, we tested whether cfDNA isolation on the
automated platforms (QS/MX) was beneficially or
adversely affected by the addition of cRNA using mul-
tiple readouts. We added varying amounts of cRNA
to the plasma samples and measured the resulting
cfDNA concentration by Qubit and TERT qPCR for
both automated platforms. Using Qubit as readout,
the addition of cRNA increased the total amount of
cfDNA extracted on both platforms (MX P < 0.001;
QS P < 0.001; Fig. 1A). However, using TERT qPCR
as readout, this increase could not be reproduced
(Fig. 1B). Next, we assessed the impact of cRNA on
the recovery of spiked-in synthetic plant DNA. Addi-
tion of cRNA affected the recovery efficiency of plant
DNA (MX P = 0.02; QS P = 0.04; Fig. 1C). Indepen-
dent of cRNA input, recovery of plant DNA was
~ 30% higher with QS (58.37  9.52) than with MX
(28.22  6.67; P < 0.001). To assess whether the
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addition of cRNA biased the isolation of particular
cfDNA fragment sizes, we performed the b-actin frag-
mentation assay (Fig. 1D). For both methods, increas-
ing amounts of cRNA reduced the number of small
fragments (136 bp; MX P = 0.001; QS P < 0.001),
while no effect on larger fragments was observed. For
all post hoc analyses, paired testing of samples with
and without addition of cRNA (0 lg) did not reveal
any significant differences.
3.2. Compatibility of CellSave preservative tubes
with different isolation platforms
Previously, we have demonstrated the good perfor-
mance of CellSave preservative tubes for ctDNA anal-
ysis (van Dessel et al., 2017). However, the
manufacturers of both automated platforms recom-
mend to use plasma isolated from blood collected in
EDTA tubes. To allow for a fair comparison with our
CellSave QA results, we therefore first determined
whether the automated platforms (QS/MX) were com-
patible with CellSave tubes by assessing the cfDNA
quantity and quality.
Figure 2A shows cfDNA concentrations as mea-
sured by TERT qPCR analysis. For the MX platform,
the median cfDNA concentration was 5.59 ngmL1
plasma from EDTA tubes and was 2.19 ngmL1
plasma from CellSave tubes (IQR: 5.06–6.21 and 2.07–
3.37 ngmL1 plasma, respectively; P = 0.008). For the
QS platform, the median cfDNA concentration was
17.17 ngmL1 plasma from EDTA tubes and
11.13 ngmL1 plasma from CellSave tubes (IQR: 7.81–
22.12 and 9.02–14.14 ngmL1 plasma, respectively).
Although this was comparable, EDTA samples dis-
played a larger range in yielded cfDNA concentration.
The potential effect of CellSave tubes on the recovery
Fig. 1. Effect of increasing cRNA input (0–4 lg) on cfDNA quantity and quality using the Maxwell and QIAsymphony platforms. The effect
on cfDNA concentration (ngmL1 plasma) was measured by Qubit (A) and TERT qPCR (B). The recovery efficiency of each platform was
analyzed by qPCR using spiked-in synthetic plant DNA (C). Differences in cfDNA fragment size, expressed as number of b-actin fragments
for each fragment size (136, 420 and 2000 bp), were analyzed by dPCR (D). Boxes (interquartile ranges; IQR) and whiskers (1.59 IQR) are
shown together with the median (black horizontal line). Outliers are indicated as single black points. Symbols ● and ▲ are mean values
shown with whiskers (standard deviation). The Friedman test was used to test the group difference between Maxwell and QIAsymphony
samples. Significant differences were post hoc analyzed using the Wilcoxon signed-rank test. N = 5.
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of synthetic plant DNA was determined as well. Com-
parable recovery efficiencies were observed in plasma
collected in EDTA and CellSave tubes for both plat-
forms (39.92% vs. 44.27% in MX and 67.92% vs.
66.19% in QS; Fig. 2B). Finally, we used the b-actin
fragmentation assay to evaluate cfDNA fragmentation
patterns as a readout for general sample quality
(Fig. 2C). EDTA tubes yielded a higher number of
large cfDNA fragments (2000 bp) irrespective of the
platform used (median number of b-actin fragments
and IQR MX: 33.08 (14.28–44.59); QS: 32.46 (25.53–
55.44)) than CellSave tubes (median number of b-actin
fragments and IQR MX: 5.15 (2.42–9.17); QS: 13.80
(7.01–18.18); P = 0.008). The number of small DNA
fragments (136 bp) did not differ between EDTA and
CellSave tubes for MX, but was slightly higher for
Fig. 2. Compatibility of EDTA and CellSave blood collection tubes with the Maxwell and QIAsymphony platforms. The effects on cfDNA
concentration (ngmL1 plasma) measured by TERT qPCR (A), recovery efficiency measured by plant DNA qPCR (B), and b-actin
fragmentation assay analyzed with dPCR are shown (C). Boxes (interquartile ranges; IQR) and whiskers (1.59 IQR) are shown together with
the median (black horizontal line). Outliers are indicated as single black points. Symbols ● and ▲ are mean values shown with whiskers
(standard deviation). The Wilcoxon signed-rank test was used to test the difference between blood collection tubes for each platform.
N = 9.
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EDTA tubes on the QS platform (median number of b-
actin fragments and IQR EDTA: 142.71 (110.28–
198.18); CellSave: 89.71 (80.22–102.64); P = 0.04).
Based on these results, we deemed CellSave tubes are
compatible with both automated platforms and used
them for all further experiments.
3.3. Comparison of the performance of
automated platforms on downstream cfDNA and
ctDNA analyses
Next, we compared the quantity and quality of the
obtained cfDNA using the current ‘gold standard’ manual
QA platform to the automated QS and MX platforms
using samples from 10 HBDs and 10 metastatic cancer
patients. In HBDs, cfDNA concentrations measured by
TERT qPCR analysis were comparable for all three isola-
tion platforms (Fig. 3A). In patients, the MX retrieved
significantly less cfDNA compared to both QA
(P = 0.002) and QS (P = 0.002; median cfDNA concen-
tration and IQR QA: 15.84 (12.64–65.11); MX: 6.00
(3.80–20.43); QS: 14.50 (11.99–57.65) ngmL1 plasma;
Fig. 3A). To determine the recovery efficiency of the three
different platforms, 5 lL of synthetic plant DNA was
added to each plasma sample preceding cfDNA isolation.
The average recovery efficiency using QA
(51.95  12.02%) was similar to QS (43.45  8.21%).
However, MX performed worse (18.61  5.81%;
Fig. 3. Effect of the different isolation platforms (QIAamp, Maxwell, and QIAsymphony) on downstream cfDNA analysis. cfDNA was
isolated from 2 mL matched plasma samples of HBDs (N = 10) and patients with metastatic cancer (N = 10) and analyzed by TERT qPCR
assay for cfDNA concentration (ngmL1 plasma) (A), plant DNA qPCR assay to determine recovery efficiency (B), and dPCR b-actin
fragmentation assay to evaluate cfDNA fragment sizes (C). Boxes (interquartile ranges; IQR) and whiskers (1.59 IQR) are shown together
with the median (black horizontal line). Outliers are indicated as single black points. Symbols ■, ●, and ▲ are mean values shown with
whiskers (standard deviation). The Friedman test was used to test the group difference between matched samples processed by the three
platforms. Significant differences were post hoc analyzed using the Wilcoxon signed-rank test.
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P < 0.001; Fig. 3B). In HBDs, we did not observe cfDNA
fragment size differences between either of the evaluated
platforms (Fig. 3C). In patients, MX isolated fewer small
b-actin fragments (136 bp) than QA (median number of
b-actin fragments and IQR for MX: 57.45 (53.17–66.72);
and for QA: 83.18 (70.36–101.63); P < 0.01) and fewer
large fragments (2000 bp) than QS (median number of b-
actin fragments and IQR for MX: 2.08 (0.00–5.21); and
for QS: 10.06 (6.70–13.72); P = 0.002).
Finally, we compared somatic variant detection in
ctDNA isolated by the different platforms. For this
purpose, we used previously generated diagnostic
sequencing results on the somatic variant status in the
primary and/or metastatic lesions of the corresponding
patients (Table 1). We detected the expected somatic
variants in all patients for all isolation methods. QS
results were most comparable to QA (Fig. 4). In MX,
fewer mutant molecules, though not significant, and
significantly fewer wild-type molecules were isolated
(Fig. 4A,B). However, this did not result in a signifi-
cantly different VAF (Fig. 4C).
4. Discussion
Up to now, several studies have investigated the effect
of manual and automated cfDNA isolation platforms
on ctDNA quantity and quality (Devonshire et al.,
2014; Perez-Barrios et al., 2016; Sorber et al., 2017).
However, differences in pre-analytical conditions,
including plasma processing time, type of blood collec-
tion tube used, and storage conditions, hamper direct
comparisons and straightforward conclusions. Here,
we presented a study in which we have systematically
optimized and compared automated isolation of
cfDNA using QS and MX with the ‘gold standard’
QA.
The addition of carrier molecules like cRNA to
plasma preceding cfDNA isolation increases the
amount of cfDNA recovered during isolation by pre-
cipitating and binding of small molecules (Kishore
et al., 2006; Shaw et al., 2009). The manual QA plat-
form requires addition of cRNA for the standard pro-
tocol, whereas the manufacturer’s protocol of both the
Fig. 4. Somatic variant detection in patients with metastatic cancer on samples isolated with the three different isolation platforms
(QIAamp, Maxwell, and QIAsymphony). Somatic variant status had been assessed in patients’ primary and/or metastatic lesion as part of
the standard of care. In all patients (N = 10), the known somatic variant was detected in plasma isolated from the three platforms. The
ratios of the mutant copy number (A), wild-type copy number (B), and variant allele frequency (VAF;C) measured in the Maxwell and
QIAsymphony vs. QIAamp are shown. The dashed line (ratio of 1) resembles the situation when platforms have similar results. The
Wilcoxon signed-rank test was used to test the difference between the platforms.
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QS and MX does not require this. In a small pilot
study, we observed that the addition of cRNA to the
QS protocol improved cfDNA yield, so cRNA was
implemented into our standard QS protocol. However,
Invitrogen has reported that cRNA might interfere
with Qubit-based DNA quantification. Indeed, our
findings suggest that the increase in cfDNA concentra-
tion as measured by Qubit for QS and MX is, at least
in part, affected by the presence of cRNA. Data
obtained from the TERT and plant DNA qPCR did
not reveal any added value of cRNA to either of the
automated platforms. Moreover, our fragmentation
assay suggests that increasing amounts of cRNA
reduce the amount of small fragments. Together, our
results demonstrate that addition of cRNA to plasma
does not improve cfDNA yields using these automated
bead-based platforms.
In our previous study using the manual QA plat-
form, we demonstrated the superiority of CellSave
tubes over EDTA tubes for collecting plasma for
cfDNA/ctDNA analysis as it ensures optimal ctDNA
quality when processed within 96 h after blood draw
compared to only 24 h for EDTA tubes, enabling its
use in multicenter clinical studies (van Dessel et al.,
2017). Therefore, we investigated the compatibility of
CellSave tubes with QS and MX. On both platforms,
we observed an increase in the isolation of large
cfDNA fragments (2000 bp) in EDTA samples. This
relates to the release of intact DNA from lysed leuko-
cytes and a subsequent increase in cfDNA concentra-
tion, which we also observed here. As the recovery
efficiency was not affected in CellSave tubes and the
plasma samples were not contaminated with additional
DNA from leukocytes, we recommend the use of Cell-
Save tubes in combination with the QS or MX plat-
form.
Currently, QA is widely used for cfDNA/ctDNA
isolations, but its manual laborious and time-consum-
ing protocol renders this method unsuitable for high-
throughput isolations. The competing automated plat-
forms QS and MX both use magnetic-bead-based pro-
tocols and have comparable hands-on times. However,
costs and number of samples that can be processed per
run differ (Table 2). In HBDs, cfDNA quantity and
quality were similar on all platforms. However, in
patients we saw for all assays that QA and QS yielded
more cfDNA than MX. As this might suggest that
higher amounts of cfDNA are less efficiently isolated
by the MX platform, we spiked high amounts of frag-
mented DNA in HBD plasma and isolated this with
MX (Fig. S3). However, these high DNA amounts
were isolated efficiently by MX. Another potential
explanation for the difference in performance might be
the absence of proteinase K incubation step in the MX
protocol. Proteinase K is used in both the QA and QS
protocols and can improve cfDNA yield by inhibiting
nucleases and the release of protein-bound cfDNA.
Moreover, recovery efficiency of plant DNA was low-
est in MX. Altogether, this explains the lower yield of
mutant and wild-type molecules isolated by MX,
which may be a concern in samples with low frequent
somatic variants. However, importantly, this lower
yield did not translate into a significant difference in
detected VAF (Figs 4C and S4). These data underline
the importance of taking the used isolation method
and readout (mutant moleculesmL1 plasma or VAF)
into consideration when comparing results between
studies as well as for the diagnostic use of ctDNA. QS
and QA performed comparable in detection of abso-
lute numbers of mutant and wild-type molecules. Of
note, other publications have observed similar perfor-
mances of QA and MX in a head-to-head comparison
(Perez-Barrios et al., 2016; Sorber et al., 2017). This
could be related to differences in pre-analytical condi-
tions (e.g., type of blood collection tube, plasma vol-
ume used as input), as multiple publications have
demonstrated its relation to cfDNA quantity and qual-
ity (Haselmann et al., 2018; van Dessel et al., 2017;
Volckmar et al., 2018). In addition, we have optimized
our QA protocol by re-eluting three times and thereby
improving our cfDNA quantity. For automated mag-
netic-bead-based systems, this is not possible.
5. Conclusion
The results of this study show that the QS automated
platform has comparable performance to the ‘gold
standard’ QA and outperformed the MX platform
depending on the readout used. The QS platform is
congruent with all our predefined goals as it (a)
reduces hands-on time from 180–240 to 30 min per
run; (b) is able to process larger numbers of samples
(96 instead of 24 at a time); (c) isolates comparable
cfDNA yield with similar efficiency; and (d) has com-
parable ctDNA quantity and quality to QA. There-
fore, the QS can replace the more laborious QA
platform, especially when high-throughput cfDNA iso-
lation is needed.
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Fig. S1. Overview of the recovery efficiency of syn-
thetic plant DNA in all samples isolated with the dif-
ferent platforms (QA, MX, and QS). (A) Dot plot of
the recovery efficiency for each isolation platform, as
analyzed by plant qPCR using spiked-in synthetic
plant DNA. Samples with a recovery efficiency < 5%
or > 100% (black horizontal lines) were excluded from
the analyses. (B) Correlation between recovery effi-
ciency and cfDNA concentration (ngmL1 plasma)
measured by TERT qPCR assay. Correlations were
tested by Spearman’s rank correlation coefficient.
*P < 0.001.
Fig. S2. Effect of cRNA addition on cfDNA quantity
using the QS platform. cfDNA concentration
(ngmL1 plasma) was determined by Qubit after add-
ing increasing amounts of cRNA (0–4 lg) before start
of the plasma isolation. Boxes (interquartile ranges;
IQR) and whiskers (1.59 IQR) are shown together
with the median (black horizontal line).
Fig. S3. Performance of the MX platform using
increasing DNA input (0, 15, and 60 ngmL1 frag-
mented cell line DNA has been spiked in HBD
plasma). The effects on (A) cfDNA concentration
(ngmL1 plasma) measured by TERT qPCR, (B)
recovery efficiency measured by plant DNA qPCR,
(C) total number of mutant molecules, and (D) VAF
are shown. Boxes (interquartile ranges; IQR) and whis-
kers (1.59 IQR) are shown together with the median
(black horizontal line). Outliers are indicated as single
black points. Symbol ● is mean value shown with
whiskers (standard deviation). N = 5.
Fig. S4. Representative data images of SNP genotyp-
ing dPCR assay isolated with the different platforms
(QA, MX, and QS). A subject with an intermediate
(A), high (B) and low (C) VAF are shown. On the Y-
axis, positive FAM signal represents mutant molecules
(blue dots); on the X-axis, positive VIC signal repre-
sents wild-type molecules (red dots). Green dots reflect
the presence of a mutant and a wild-type molecule in a
single well.
Table S1. Custom primer and probe sequences used
for qPCR.
Table S2. Standard SNP genotyping assays.
Table S3. Custom SNP genotyping assays.
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